Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.

Archives of biochemistry and biophysics - 15 Jun 2005

Fricker Michael, Lograsso Philip, Ellis Semantha, Wilkie Neil, Hunt Peter, Pollack Scott J

Abstract excerpt

c-Jun N-terminal kinase (JNK) activation is linked to the aberrant cell death in several neurodegenerative disorders, including Parkinson's and Alzheimer's disease. The sequence similarity among the JNK isoforms and fellow MAP kinase family member p38 has rendered the challenge of producing JNK3-specific inhibitors difficult. Using the crystal structure of JNK3 complexed with JNK inhibitors, potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracenes
Share to Biotinylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorescence Resonance Energy Transfer

Share to Glutathione

Share to Imidazoles

Share to Inhibitory Concentration 50

Share to Isoleucine

Share to p38 Mitogen-Activated Protein Kinases

Source

Identifiers

PMID: 15907786
DOI: 10.1016/j.abb.2005.04.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.PMID 15907786Read ↗

c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s DiseasesSemantic proximity Read ↗

Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue.Semantic proximity Read ↗

Non-kinase targeting of oncogenic c-Jun N-terminal kinase (JNK) signaling: the future of clinically viable cancer treatmentsSemantic proximity Read ↗

Polypharmacological Targeting of G2019S Mutant LRRK2 and JNK3 for the Discovery of a Lead Compound against Parkinson's Disease.Semantic proximity Read ↗

Active mutants of the human p38alpha mitogen-activated protein kinase.Semantic proximity Read ↗

The isoform‐specific functions of the c‐Jun N‐terminal Kinases (JNKs): differences revealed by gene targetingSemantic proximity Read ↗

Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's diseaseSemantic proximity Read ↗

Reverse two-hybrid screening identifies residues of JNK required for interaction with the kinase interaction motif of JNK-interacting protein-1.Semantic proximity Read ↗

Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1.Semantic proximity Read ↗

'Polymorphism-aided' Selective Targeting and Inhibition of Caspase-6 by a Novel Allosteric Inhibitor Towards Efficient Alzheimer's Disease Treatment.Semantic proximity Read ↗

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity.Semantic proximity Read ↗

JX401, A p38alpha inhibitor containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.